Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma

Table 3

Final selected CTL epitopes from CD70 protein for constructing multiepitope vaccine witht their corresponding MHC Class I alleles and immunogenic traits.

Protein name	Position	Epitope sequence	No. of allels	Allels	NetMHCpan average rank scores	Allergenicity	Antigenicity	Toxicity
CD70	43–55	QAQQQLPLESLGW	9	HLA-B58:01; HLA-B39:01; HLA-B15:01; HLA-B13:01; HLA-B40:01; HLA-B08:01; HLA-A32:01; HLA-A24:02; HLA-B35:01	1.027	Nonallergen	0.6649	Non
	70–83	DPRLYWQGGPALGR	10	HLA-B07:02; HLA-A24:02; HLA-A02:01; HLA-B15:01; HLA-A32:01; HLA-B13:01; HLA-A03:01; HLA-A11:01; HLA-B39:01; HLA-A33:01	0.683	Nonallergen	0.6572	Non
	72–86	RLYWQGGPALGRSFL	11	HLA-A02:01; HLA-A24:02; HLA-B07:02; HLA-B15:01; HLA-A32:01; HLA-B13:01; HLA-A03:01; HLA-A11:01; HLA-B39:01; HLA-A33:01; HLA-B35:01	0.664	Nonallergen	0.5323	Non
CD70 (Homo sapiens)	99–112	HRDGIYMVHIQVTL	8	HLA-B39:01; HLA-B27:05; HLA-A02:01; HLA-A24:02; HLA-B08:01; HLA-B15:01; HLA-A32:01; HLA-B13:01	0.778	Nonallergen	0.9996	Non
	118–132	TTASRHHPTTLAVGI	10	HLA-B39:01; HLA-B07:02; HLA-B08:01; HLA-B58:01; HLA-B15:01; HLA-A30:01; HLA-A32:01; HLA-B13:01; HLA-B27:05; HLA-B35:01	0.886	Nonallergen	0.9327	Non
	134–147	SPASRSISLLRLSF	16	HLA-B07:02; HLA-B08:01; HLA-B39:01; HLA-B35:01; HLA-A33:01; HLA-A68:01; HLA-A03:01; HLA-A11:01; HLA-A30:01; HLA-B27:05; HLA-B58:01; HLA-B15:01; HLA-A32:01; HLA-A24:02; HLA-A26:01; HLA-B13:01	0.605	Nonallergen	1.1247	Non
	138–147	RSISLLRLSF	10	HLA-B58:01; HLA-A30:01; HLA-B15:01; HLA-A32:01; HLA-A24:02; HLA-A26:01; HLA-B07:02; HLA-B08:01; HLA-B13:01; HLA-B35:01	0.872	Nonallergen	1.4089	Non

Lower rates show better binding affinity. Higher rate shows high degree of peptide antigenicity.